Characterization of lactobacilli strains isolated from baby’s feces for their potential immunobiotic application
Background and Objectives: Several LAB species were evaluated and characterized for potential probiotic use. Besides the antimicrobial activity, probiotics showed recently a capacity to prevent and to alleviate inflammatory and chronic diseases. Immunomodulation effect is one of the modes of actions of such probiotics, called immunobiotics, which can be used in several chronic diseases such as Inflammatory Bowel Diseases (IBD). The aim of this study was to isolate, identify and characterize lactobacilli strains from healthy baby’s feces in order to select some strains with potential immunobiotic application especially strains which can stimulate anti-inflammatory responses.
Materials and Methods: Forty-two LAB strains were isolated and identified by the MALDI-TOF / MS technique. In addition, strains were subjected to several assessments such as antimicrobial activity, the capacity to form biofilm in polystyrene microplate and immunomodulation activity in a PBMC model.
Results: Results showed that the majority of strains (90.4%) were identified as Lactobacillus. However, among these, only 39.4% of lactobacilli strains were not identified at the species level. All isolated lactobacilli strains showed an anti-inflammatory effect. Moreover, 7 strains were considered as good probiotic candidates based on their characteristics such as their antibacterial activities, formation of the strongest biofilm and their ability to stimulate an anti-inflammatory response in PBMCs model.
Conclusion: Two strains (Lactobacillus spp S14 and Lactobacillus spp S49) which showed the best immunobiotic characteristics, could be selected and evaluated more deeply in vivo model as well as in human clinical study to ensure their effectiveness in inflammatory diseases such as IBD.
2. Ursell LK, Haiser HJ, Van Treuren W, Garg N, Reddivari L, Vanamala J, et al. The intestinal metabolome: an intersection between microbiota and host. Gastroenterolog 2014; 146:1470-1476.
3. Hooks KB, O'Malley MA. Dysbiosis and its discontents. MBio 2017; 8(5): e01492-1417.
4. Petersen C, Round JL. Defining dysbiosis and its influence on host immunity and disease. Cell Microbiol 2014; 16:1024-1033.
5. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444:1022-1023.
6. Wang B, Jiang X, Cao M, Ge J, Bao Q, Tang L, et al. Altered fecal microbiota correlates with liver biochemistry in nonobese patients with non-alcoholic fatty liver disease. Sci Rep 2016; 6:32002.
7. Hsiao WWL, Metz C, Singh DP, Roth J. The microbes of the intestine: an introduction to their metabolic and signaling capabilities. Endocrinol Metab Clin North Am 2008; 37:857-871.
8. Zhang H Cai Y, editors. Lactic Acid Bacteria: Fundamentals and Practice. Springer Netherlands; 2014.
9. Kassaa IA, Rafei R, Moukhtar M, Zaylaa M, Gharsallaoui A, Asehraou A, et al. LABiocin database: a new database designed specifically for Lactic Acid Bacteria bacteriocins. Int J Antimicrob Agents 2019; S0924-8579(19)30192-X.
10. Ashraf R, Shah NP. Immune system stimulation by probiotic microorganisms. Crit Rev Food Sci Nutr 2014; 54:938-956.
11. Gómez NC, Ramiro JMP, Quecan BXV, de Melo Franco BDG. Use of potential probiotic lactic acid bacteria (LAB) biofilms for the control of Listeria monocytogenes, Salmonella Typhimurium, and Escherichia coli O157:H7 biofilms formation. Front Microbiol 2016; 7:863.
12. Kizerwetter-Świda M, Binek M. Assessment of potentially probiotic properties of Lactobacillus strains isolated from chickens. Pol J Vet Sci 2016; 19:15-20.
13. Lee YK, Puong KY. Competition for adhesion between probiotics and human gastrointestinal pathogens in the presence of carbohydrate. Br J Nutr 2002; 88 Suppl 1:S101-108.
14. Lomax AR, Calder PC. Probiotics, immune function, infection and inflammation: a review of the evidence from studies conducted in humans. Curr Pharm Des 2009; 15:1428-1518.
15. Morrow LE, Gogineni V, Malesker MA. Probiotic, prebiotic, and synbiotic use in critically ill patients. Curr Opin Crit Care 2012; 18:186-191.
16. Simpson PJ, Fitzgerald GF, Stanton C, Ross RP. The evaluation of a mupirocin-based selective medium for the enumeration of bifidobacteria from probiotic animal feed. J Microbiol Methods 2004; 57:9-16.
17. Kassaa IA, Zaylaa M, Hussein S, Omari KE, Chihib N-E, Hamze M, et al. Identification of the first bacteriocin isolated in Lebanon extracted via a modified adsorption-desorption method and its potential food application. Int Arabic J Antimicrob Agents 2018; 8:2.
18. Ait Ouali F, Al Kassaa I, Cudennec B, Abdallah M, Bendali F, Sadoun D, et al. Identification of lactobacilli with inhibitory effect on biofilm formation by pathogenic bacteria on stainless steel surfaces. Int J Food Microbiol 2014; 191:116-124.
19. Borges S, Silva J, Teixeira P. Survival and biofilm formation by Group B streptococci in simulated vaginal fluid at different pHs. Antonie Van Leeuwenhoek 2012; 101:677-682.
20. Foligne B, Nutten S, Grangette C, Dennin V, Goudercourt D, Poiret S, et al. Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World J Gastroenterol 2007; 13:236-243.
21. Zaylaa M, Al Kassaa I, Alard J, Peucelle V, Boutillier D, Desramaut J, et al. Probiotics in IBD: Combining in vitro and in vivo models for selecting strains with both anti-inflammatory potential as well as a capacity to restore the gut epithelial barrier. J Funct Foods 2018; 47:304-315.
22. Singhal N, Kumar M, Kanaujia PK, Virdi JS. MALDI-TOF mass spectrometry: an emerging technology for microbial identification and diagnosis. Front Microbiol 2015; 6:791.
23. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284:1318-1322.
24. Saxelin M, Tynkkynen S, Mattila-Sandholm T, de Vos WM. Probiotic and other functional microbes: from markets to mechanisms. Curr Opin Biotechnol 2005; 16:204-211.
25. Lewis K. Riddle of biofilm resistance. Antimicrob Agents Chemother 2001; 45:999-1007.
26. Liu Y, Yang S-F, Li Y, Xu H, Qin L, Tay J-H. The influence of cell and substratum surface hydrophobicities on microbial attachment. J Biotechnol 2004; 110:251-256.
27. Salas-Jara MJ, Ilabaca A, Vega M, García A. Biofilm forming Lactobacillus: New challenges for the development of probiotics. Microorganisms 2016; 4:E35.
28. Filloux A, Vallet I. [Biofilm: set-up and organization of a bacterial community]. Med Sci (Paris) 2003; 19:77-83.
29. Nigam A, Kumar A, Hv M, Bhola N. In-vitro Screening of antibacterial activity of lactic acid bacteria against common enteric pathogens. J Biomed Sci 2012; 1:2.
30. Elayaraja S, Annamalai N, Mayavu P, Balasubramanian T. Production, purification and characterization of bacteriocin from Lactobacillus murinus AU06 and its broad antibacterial spectrum. Asian Pac J Trop Biomed 2014; 4(Suppl 1):S305-311.
31. Zendo T, Nakayama J, Fujita K, Sonomoto K. Bacteriocin detection by liquid chromatography/mass spectrometry for rapid identification. J Appl Microbiol 2008; 104:499-507.
32. CDU-HGE. Les fondamentaux de la pathologie digestive - 9782294731181 | Elsevier Masson - Livres, ebooks, revues et traités EMC pour toutes spécialités médicales et paramédicales. Available from: URL: https://www.elsevier-masson.fr/les-fondamentaux-de-la-pathologie-digestive-9782294731181.html
33. Rocha-Ramírez LM, Pérez-Solano RA, Castañón-Alonso SL, Moreno Guerrero SS, Ramírez Pacheco A, García Garibay M, et al. Probiotic Lactobacillus strains stimulate the inflammatory response and activate human macrophages. J Immunol Res 2017; 2017:4607491.